Program
Cyclophosphamide
Also written as “cyclophosphamide”, “Cyclophosphamide,Fludarabine” and “Cytoxan”.
Its studies are mostly in Breast Neoplasms · Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Leukemia, Lymphocytic, Chronic, B-Cell · Carcinoma, Non-Small-Cell Lung, led by 28 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 151 open or running | phase 4since Jan 4, 2011 | Oct 16, 2007 | Feb 28, 2028phase 2 · NCT04931342 |
| Beijing Biotech | 99 open or running | phase 2since Apr 5, 2026 | Mar 14, 2026 | Feb 18, 2027phase 1 · NCT07480941 |
| ImmunoVaccine Technologies, Inc. (IMV Inc.) | 63 open or running | phase 2since Dec 12, 2014 | Dec 12, 2014 | none ahead |
| Amgen | 40 open or running | phase 2since Jul 5, 2000 | Jul 5, 2000 | none ahead |
| Sanofi | 40 open or running | phase 3since Jul 11, 2001 | Jul 11, 2001 | none ahead |
| Takeda | 41 open or running | phase 2since Jul 25, 2007 | Jul 25, 2007 | none ahead |
| Allogene Therapeutics | 32 open or running | phase 2since Dec 8, 2022 | Dec 8, 2022 | Dec 2027phase 2 · NCT06500273 |
| Bristol-Myers Squibb | 21 open or running | phase 2since Dec 22, 2016 | Dec 22, 2016 | Mar 15, 2029phase 1 · NCT07115745 |
| hangzhou-huasai-biomedicine-co-ltd | 22 open or running | phase 1since Jul 22, 2025 | Jul 22, 2025 | Aug 30, 2027phase 1 · NCT07105176 |
| rampart-health-l-l-c | 21 open or running | phase 2since Aug 9, 2019 | Aug 9, 2019 | none ahead |
| shanghai-first-song-biotechnology-co-ltd | 21 open or running | early phase 1since Jul 30, 2024 | Jul 30, 2024 | none ahead |
| adicet-therapeutics | 10 open or running | phase 1since Jan 26, 2021 | Jan 26, 2021 | none ahead |
| aryogen-pharmed-co | 10 open or running | phase 3since Nov 21, 2017 | Nov 21, 2017 | none ahead |
| caribou-biosciences-inc | 11 open or running | phase 1since Nov 16, 2020 | Nov 16, 2020 | none ahead |
| carsgen-therapeutics-co-ltd | 10 open or running | phase 1since Aug 9, 2016 | Aug 9, 2016 | none ahead |
| criterium-inc | 10 open or running | phase 1since Aug 7, 2012 | Aug 7, 2012 | none ahead |
| Gilead Sciences | 10 open or running | phase 1since Oct 13, 2017 | Oct 13, 2017 | none ahead |
| Merck | 10 open or running | phase 2since Oct 23, 2008 | Oct 23, 2008 | none ahead |
| Merck KGaA, Darmstadt, Germany | 10 open or running | phase 1since Oct 11, 2012 | Oct 11, 2012 | none ahead |
| neukio-biotherapeutics-shanghai-co-ltd | 11 open or running | early phase 1since Aug 19, 2025 | Aug 19, 2025 | Jan 14, 2027early phase 1 · NCT07144462 |
| nkarta-inc | 11 open or running | phase 1since Sep 25, 2020 | Sep 25, 2020 | none ahead |
| Oncotherapeutics | 10 open or running | phase 2since Jul 30, 2014 | Jul 30, 2014 | none ahead |
| precision-biosciences-inc | 10 open or running | phase 2since Jul 19, 2019 | Jul 19, 2019 | none ahead |
| Sangamo Therapeutics | 10 open or running | phase 2since Aug 22, 2014 | Aug 22, 2014 | none ahead |
| Sarah Cannon Research Institute | 10 open or running | phase 2since Jun 27, 2007 | Jun 27, 2007 | none ahead |
| seah-lim-m-d | 10 open or running | phase 2since Aug 29, 2012 | Aug 29, 2012 | none ahead |
| shanghai-unicar-therapy-bio-medicine-technology-co-ltd | 11 open or running | phase 1since Mar 28, 2021 | Mar 28, 2021 | none ahead |
| tty-biopharm | 10 open or running | phase 2since Aug 31, 2010 | Aug 31, 2010 | none ahead |
Also a collaborator on its studies: Natera, Incyte, AbbVie and Johnson & Johnson.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 40 studies since Oct 16, 2007.
- Feb 7, 2022Phase 2 study in Platinum-resistant Epithelial Ovarian CancerImmunoVaccine Technologies, Inc. (IMV Inc.) · NCT05243524 · 16 enrolled · United States, Canada, Puerto Rico
- Dec 8, 2022Allogene Therapeutics's first study: phase 2 study in RecurrenceNew to Allogene TherapeuticsAllogene Therapeutics · NCT05714345 · 2 enrolled · United States, Belgium
- Jan 4, 2023Phase 2 study in LymphomaTakeda · NCT05673785 · 52 enrolled · China
- Jun 26, 2024Phase 2 study in Lymphoma, Large B-Cell, DiffuseAllogene Therapeutics · NCT06500273 · 250 planned · United States, Australia, Canada and more
- Jul 30, 2024shanghai-first-song-biotechnology-co-ltd's first studies: 2 early phase 1 studiesNew to shanghai-first-song-biotechnology-co-ltdshanghai-first-song-biotechnology-co-ltd · NCT06532643, NCT06532630
- Feb 7, 2025Phase 1 study in Autoimmune DiseasesBristol-Myers Squibb · NCT07115745 · 125 planned · United States, Australia, Brazil and more
- Jul 8, 2025Phase 1 study in Lupus Erythematosus, SystemicAllogene Therapeutics · NCT07085104 · 66 planned · United States, Canada
- Jul 22, 2025hangzhou-huasai-biomedicine-co-ltd's first study: phase 1 study in Advanced Non-Small Cell Lung CancerNew to hangzhou-huasai-biomedicine-co-ltdhangzhou-huasai-biomedicine-co-ltd · NCT07105176 · 12 planned · China
- Aug 19, 2025neukio-biotherapeutics-shanghai-co-ltd's first study: early phase 1 study in AutoimmuneNew to neukio-biotherapeutics-shanghai-co-ltdneukio-biotherapeutics-shanghai-co-ltd · NCT07144462 · 8 planned · China
- Mar 14, 2026Beijing Biotech's first studies: 2 phase 1 studiesNew to Beijing BiotechBeijing Biotech · NCT07480941, NCT07492628
- Apr 5, 20263 phase 2 studiesPhase 2 reachedBeijing Biotech · NCT07523542, NCT07523529, NCT07551362
- Apr 18, 2026Phase 1 study in GliomaBeijing Biotech · NCT07551336 · 36 planned · China
- May 14, 20263 phase 2 studiesBeijing Biotech · NCT07598955, NCT07617805, NCT07617753
- Sep 15, 2026Phase 1 study in Advanced NSCLChangzhou-huasai-biomedicine-co-ltd · NCT07830342 · 24 planned · China
Ahead
- Jan 14, 2027Primary completion: early phase 1 study in Autoimmuneneukio-biotherapeutics-shanghai-co-ltd · NCT07144462
- Feb 18, 2027Primary completion: phase 1 study in GlioblastomaBeijing Biotech · NCT07480941
- Mar 14, 2027Primary completion: phase 2 study in RecurrenceBeijing Biotech · NCT07617805
- Mar 14, 2027Primary completion: phase 2 study in Stomach NeoplasmsBeijing Biotech · NCT07551362
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The newest 60 of 70 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07830342Advanced NSCLC · China | 1 | Recruiting | hangzhou-huasai-biomedicine-co-ltd | Oct 2028 | 24 |
| NCT07617805Recurrence · China | 2 | Recruiting | Beijing Biotech | Mar 14, 2027 | 42 |
| NCT07617753Carcinoma, Ovarian Epithelial · China | 2 | Recruiting | Beijing Biotech | Jun 14, 2027 | 36 |
| NCT07598955Thymoma · China | 2 | Recruiting | Beijing Biotech | Jun 14, 2027 | 36 |
| NCT07551362Stomach Neoplasms · China | 2 | Recruiting | Beijing Biotech | Mar 14, 2027 | 36 |
| NCT07551336Glioma · China | 1 | Recruiting | Beijing Biotech | Apr 14, 2027 | 36 |
| NCT07523542Lupus Erythematosus, Systemic · China | 2 | Recruiting | Beijing Biotech | Mar 14, 2027 | 24 |
| NCT07523529Neoplasm Metastasis · China | 2 | Recruiting | Beijing Biotech | Apr 14, 2027 | 72 |
| NCT07492628Urinary Bladder Neoplasms · China | 1 | Recruiting | Beijing Biotech | Jun 14, 2027 | 42 |
| NCT07480941Glioblastoma · China | 1 | Recruiting | Beijing Biotech | Feb 18, 2027 | 36 |
| NCT07144462Autoimmune · China | Early 1 | Recruiting | neukio-biotherapeutics-shanghai-co-ltd | Jan 14, 2027 | 8 |
| NCT07105176Advanced Non-Small Cell Lung Cancer · China | 1 | Recruiting | hangzhou-huasai-biomedicine-co-ltd | Aug 30, 2027 | 12 |
| NCT07085104Lupus Erythematosus, Systemic · United States, Canada | 1 | Recruiting | Allogene Therapeutics | Feb 2028 | 66 |
| NCT07115745Autoimmune Diseases · United States, Australia, Brazil and more | 1 | Recruiting | Bristol-Myers Squibb | Mar 15, 2029 | 125 |
| NCT06532643Lymphoma · China | Early 1 | UNKNOWN | shanghai-first-song-biotechnology-co-ltd | Sep 1, 2025 | 9 |
| NCT06532630B-Cell Malignancy · China | Early 1 | Recruiting | shanghai-first-song-biotechnology-co-ltd | Sep 1, 2025 | 9 |
| NCT06500273Lymphoma, Large B-Cell, Diffuse · United States, Australia, Canada and more | 2 | Recruiting | Allogene Therapeutics | Dec 2027 | 250 |
| NCT05673785Lymphoma · China | 2 | Active, not recruiting | Takeda | Apr 27, 2025 | 52 |
| NCT05714345Recurrence · United States, Belgium | 2 | Terminated | Allogene Therapeutics | Feb 20, 2024 | 2 |
| NCT05243524Platinum-resistant Epithelial Ovarian Cancer · United States, Canada, Puerto Rico | 2 | Terminated | ImmunoVaccine Technologies, Inc. (IMV Inc.) | Jul 24, 2023 | 16 |
| NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | Hoffmann-La Roche | Feb 28, 2028 | 176 |
| NCT04920617Lymphoma, Large B-Cell, Diffuse · United States, Australia, Canada and more | 2 | Recruiting | ImmunoVaccine Technologies, Inc. (IMV Inc.) | Oct 2024 | 102 |
| NCT04825496Recurrence · China | 1 | Recruiting | shanghai-unicar-therapy-bio-medicine-technology-co-ltd | Dec 31, 2023 | 18 |
| NCT04790903Lymphoma, Large B-Cell, Diffuse · United States, France, Italy and more | 1 | Terminated | Hoffmann-La Roche | May 21, 2024 | 50 |
| NCT04735471Lymphoma, Follicular · United States | 1 | Terminated | adicet-therapeutics | Feb 3, 2025 | 34 |
| NCT04713371Neoplasm Metastasis · United States | 2 | Active, not recruiting | rampart-health-l-l-c | Dec 2024 | 32 |
| NCT04637763Lymphoma, Non-Hodgkin · United States, Australia, Israel | 1 | Active, not recruiting | caribou-biosciences-inc | Sep 11, 2025 | 72 |
| NCT04623944Leukemia, Myeloid, Acute · United States | 1 | Active, not recruiting | nkarta-inc | Oct 2, 2024 | 61 |
| NCT04090775Metastatic Prostatic Adenocarcinoma · United States | 2 | Completed | rampart-health-l-l-c | Jul 30, 2020 | 12 |
| NCT04030195Lymphoma, Non-Hodgkin · United States | 2 | Completed | precision-biosciences-inc | Jun 24, 2021 | 18 |
| NCT03836352Ovarian Neoplasms · United States, Canada | 2 | Active, not recruiting | ImmunoVaccine Technologies, Inc. (IMV Inc.) | Dec 31, 2023 | 184 |
| NCT03425656Breast Neoplasms · Iran, Islamic Republic of | 3 | Completed | aryogen-pharmed-co | Mar 6, 2018 | 108 |
| NCT03332576Carcinoma, Ovarian Epithelial · United States, Canada | 1 | Completed | ImmunoVaccine Technologies, Inc. (IMV Inc.) | Sep 8, 2016 | 37 |
| NCT03318861Multiple Myeloma · United States | 1 | Terminated | Gilead Sciences | Dec 17, 2018 | 17 |
| NCT03003520Lymphoma, Large B-Cell, Diffuse · United States, Austria, Denmark and more | 2 | Completed | Bristol-Myers Squibb | Apr 24, 2022 | 46 |
| NCT02876978Lung Squamous Cell Carcinoma · China | 1 | UNKNOWN | carsgen-therapeutics-co-ltd | Oct 2017 | 20 |
| NCT02785250Carcinoma, Ovarian Epithelial · United States, Canada | 2 | Active, not recruiting | ImmunoVaccine Technologies, Inc. (IMV Inc.) | Oct 2020 | 85 |
| NCT02693210Arthritis, Rheumatoid · Australia, Belgium, Canada and more | 2 | Completed | Hoffmann-La Roche | Aug 2002 | 161 |
| NCT02605915Breast Neoplasms · United States | 1 | Completed | Hoffmann-La Roche | Nov 13, 2019 | 98 |
| NCT02533401Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Venezuela | 2 | Completed | Hoffmann-La Roche | Dec 2014 | 34 |
| NCT02419742Breast Neoplasms · India | 4 | Completed | Hoffmann-La Roche | Jun 24, 2021 | 110 |
| NCT02323230Lymphoma, Large B-Cell, Diffuse · Canada | 2 | Terminated | ImmunoVaccine Technologies, Inc. (IMV Inc.) | Jun 2017 | 4 |
| NCT02225665Acquired Immunodeficiency Syndrome · United States | 2 | Completed | Sangamo Therapeutics | Jun 2018 | 8 |
| NCT02206425Multiple Myeloma · United States | 2 | Completed | Oncotherapeutics | Jan 19, 2018 | 45 |
| NCT02055820Lymphoma, Non-Hodgkin · United States, Australia, Austria and more | 2 | Completed | Hoffmann-La Roche | Jun 28, 2017 | 267 |
| NCT01980589Multiple Myeloma · United States | 1 | Completed | Amgen | Mar 2016 | 22 |
| NCT01731587Carcinoma, Non-Small-Cell Lung | 1 | Withdrawn | Merck KGaA, Darmstadt, Germany | 0 | |
| NCT01679041Multiple Sclerosis · United States | 2 | Terminated | seah-lim-m-d | Nov 2013 | 1 |
| NCT01660750Multiple Myeloma · United States | 1 | Completed | criterium-inc | Aug 2015 | 29 |
| NCT01649856Lymphoma, Large B-Cell, Diffuse · Algeria, Argentina, Belgium and more | 3 | Completed | Hoffmann-La Roche | Oct 21, 2014 | 572 |
| NCT01292603Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Australia, Brazil and more | 1 | Completed | Hoffmann-La Roche | May 7, 2014 | 240 |
| NCT01283386Leukemia, Lymphocytic, Chronic, B-Cell · Russian Federation | 4 | Terminated | Hoffmann-La Roche | Mar 16, 2016 | 26 |
| NCT01271010Leukemia, Lymphocytic, Chronic, B-Cell · Russian Federation | 4 | Terminated | Hoffmann-La Roche | May 4, 2016 | 89 |
| NCT01263704Leukemia, Lymphocytic, Chronic, B-Cell · Israel | 2 | Completed | Hoffmann-La Roche | Apr 3, 2017 | 42 |
| NCT01210768Breast Neoplasms · Taiwan | 2 | UNKNOWN | tty-biopharm | Oct 31, 2022 | 254 |
| NCT00779129Breast Neoplasms | 2 | Completed | Merck | Aug 2007 | 70 |
| NCT00773695Breast Neoplasms · Norway | 2 | Completed | Hoffmann-La Roche | Nov 9, 2022 | 150 |
| NCT00718549Leukemia, Lymphocytic, Chronic, B-Cell · Belarus, Poland | 3 | Completed | Hoffmann-La Roche | Sep 14, 2015 | 128 |
| NCT00715208Lymphoma, Follicular · United States, Puerto Rico | 2 | Completed | Takeda | Feb 2011 | 55 |
| NCT00545714Leukemia, Lymphocytic, Chronic, B-Cell · Spain | 2 | Completed | Hoffmann-La Roche | May 20, 2016 | 86 |
How it is read
Names in the registry
- “Cyclophosphamide”, 74 entries
- “cyclophosphamide”, 9 entries
- “Cyclophosphamide,Fludarabine”, 4 entries
- “Cytoxan”, 3 entries
- “CHOP”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 17 studies
- Multiple Myeloma, 11 studies
- Lymphoma, Large B-Cell, Diffuse, 9 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 8 studies
- Carcinoma, Non-Small-Cell Lung, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.